Suppr超能文献

肾上腺皮质癌的根治性切除:术后复发率及模式

Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.

作者信息

Amini Neda, Margonis Georgios Antonios, Kim Yuhree, Tran Thuy B, Postlewait Lauren M, Maithel Shishir K, Wang Tracy S, Evans Douglas B, Hatzaras Ioannis, Shenoy Rivfka, Phay John E, Keplinger Kara, Fields Ryan C, Jin Linda X, Weber Sharon M, Salem Ahmed, Sicklick Jason K, Gad Shady, Yopp Adam C, Mansour John C, Duh Quan-Yang, Seiser Natalie, Solorzano Carmen C, Kiernan Colleen M, Votanopoulos Konstantinos I, Levine Edward A, Poultsides George A, Pawlik Timothy M

机构信息

Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.

出版信息

Ann Surg Oncol. 2016 Jan;23(1):126-33. doi: 10.1245/s10434-015-4810-y. Epub 2015 Aug 18.

Abstract

BACKGROUND

Adrenocortical carcinoma (ACC) is a rare malignancy. The aim of this study was to determine the incidence and patterns of recurrence after curative-intent surgery for ACC.

METHODS

Patients who underwent curative-intent resection for ACC between 1993 and 2014 were identified from 13 academic institutions participating in the United States ACC study group. Patients with metastasis or an R2 margin were excluded. Patterns and rates of recurrence were determined and classified as locoregional and distant recurrence.

RESULTS

A total of 180 patients with a median age of 52 years (interquartile range 43-61) were identified. Most patients underwent open surgery (n = 111, 64.5 %) and had an R0 resection margin (n = 117, 75.0 %). At last follow-up, 116 patients (64.4 %) had experienced recurrence (locoregional only, n = 41, 36.3 %; distant only, n = 51, 45.1 %; locoregional and distant, n = 21, 18.6 %). Median time to recurrence was 18.8 months. Several factors were associated with locoregional recurrence, including left-sided ACC location (odds ratio [OR] 2.71, 95 % confidence interval [CI] 1.06-6.89) and T3/T4 disease (reference T1/T2, OR 3.04, 95 % CI 1.19-7.80) (both p < 0.05). Distant recurrence was associated with larger tumor size (OR 1.11, 95 % CI 1.01-1.24) and T3/T4 disease (reference T1/T2, OR 5.23, 95 % CI 1.70-16.10) (both p < 0.05). Patients with combined locoregional and distant recurrence had worse survival (3- and 5-year survival: 39.5, 19.7 %) versus patients with distant-only (3- and 5-year survival 55.1, 43.3 %) or locoregional-only recurrence (3- and 5-year survival 81.4, 64.1 %) (p = 0.01).

CONCLUSIONS

Nearly two-thirds of patients experienced disease recurrence after resection of ACC. Although a subset of patients experienced recurrence with locoregional disease only, many patients experienced recurrence with distant disease as a component of recurrence and had a poor prognosis.

摘要

背景

肾上腺皮质癌(ACC)是一种罕见的恶性肿瘤。本研究的目的是确定ACC根治性手术后的复发率和复发模式。

方法

从参与美国ACC研究组的13家学术机构中,识别出1993年至2014年间接受ACC根治性切除术的患者。排除有转移或R2切缘的患者。确定复发模式和复发率,并分为局部区域复发和远处复发。

结果

共识别出180例患者,中位年龄52岁(四分位间距43 - 61岁)。大多数患者接受了开放手术(n = 111,64.5%),且切缘为R0(n = 117,75.0%)。在最后一次随访时,116例患者(64.4%)出现复发(仅局部区域复发,n = 41,36.3%;仅远处复发,n = 51,45.1%;局部区域和远处复发,n = 21,18.6%)。复发的中位时间为18.8个月。几个因素与局部区域复发相关,包括左侧ACC位置(比值比[OR] 2.71,95%置信区间[CI] 1.06 - 6.89)和T3/T4期疾病(参照T1/T2期,OR 3.04,95% CI 1.19 - 7.80)(均p < 0.05)。远处复发与肿瘤较大(OR 1.11,95% CI 1.01 - 1.24)和T3/T4期疾病(参照T1/T2期,OR 5.23,95% CI 1.70 - 16.10)相关(均p < 0.05)。局部区域和远处联合复发的患者生存率较差(3年和5年生存率:39.5%,19.7%),而仅远处复发(3年和5年生存率55.1%,43.3%)或仅局部区域复发(3年和5年生存率81.4%,64.1%)的患者(p = 0.01)。

结论

近三分之二的患者在ACC切除术后出现疾病复发。虽然一部分患者仅出现局部区域疾病复发,但许多患者复发时伴有远处疾病,预后较差。

相似文献

1
Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.
Ann Surg Oncol. 2016 Jan;23(1):126-33. doi: 10.1245/s10434-015-4810-y. Epub 2015 Aug 18.
2
Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.
Ann Surg Oncol. 2016 Jan;23(1):134-41. doi: 10.1245/s10434-015-4803-x. Epub 2015 Aug 19.
4
Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma.
J Am Coll Surg. 2016 Dec;223(6):794-803. doi: 10.1016/j.jamcollsurg.2016.08.568. Epub 2016 Sep 13.
5
Resection of adrenocortical carcinoma liver metastasis: is it justified?
Ann Surg Oncol. 2012 Aug;19(8):2643-51. doi: 10.1245/s10434-012-2358-7. Epub 2012 Apr 21.
6
A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.
Ann Surg Oncol. 2018 Feb;25(2):520-527. doi: 10.1245/s10434-017-6236-1. Epub 2017 Nov 21.
7
Surgery for recurrent adrenocortical carcinoma: A multicenter retrospective study.
Surgery. 2017 Jan;161(1):249-256. doi: 10.1016/j.surg.2016.08.058. Epub 2016 Nov 14.
8
Adrenocortical carcinoma surgery-surgical extent and approach.
Langenbecks Arch Surg. 2016 Nov;401(7):991-997. doi: 10.1007/s00423-016-1462-8. Epub 2016 Jul 13.
9
Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma.
Ann Surg. 2012 Feb;255(2):363-9. doi: 10.1097/SLA.0b013e3182367ac3.
10
Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):252-9. doi: 10.1016/j.ijrobp.2015.01.007. Epub 2015 Mar 5.

引用本文的文献

1
Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma.
Endocrine. 2025 May;88(2):597-606. doi: 10.1007/s12020-025-04163-5. Epub 2025 Jan 25.
2
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma.
Endocr Relat Cancer. 2024 Nov 20;31(12). doi: 10.1530/ERC-24-0061. Print 2024 Dec 1.
3
Estimation of the tumor size at cure threshold among adult patients with adrenocortical carcinoma: A populational-based study.
Heliyon. 2024 Mar 22;10(7):e28160. doi: 10.1016/j.heliyon.2024.e28160. eCollection 2024 Apr 15.
4
Pediatric adrenocortical carcinoma: clinical features and application of neoadjuvant chemotherapy.
Eur J Med Res. 2023 Oct 9;28(1):411. doi: 10.1186/s40001-023-01381-3.
6
Prognostic Factors of Adrenocortical Carcinoma: Experience from a Regional Medical Center in Eastern China.
Int J Gen Med. 2023 Feb 3;16:453-465. doi: 10.2147/IJGM.S399473. eCollection 2023.
7
Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer.
Cancers (Basel). 2022 Oct 26;14(21):5245. doi: 10.3390/cancers14215245.
9
Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.
Ther Adv Chronic Dis. 2021 Jul 20;12:20406223211033103. doi: 10.1177/20406223211033103. eCollection 2021.
10
Open versus minimally invasive surgery for suspected adrenocortical carcinoma.
Transl Androl Urol. 2021 May;10(5):2246-2263. doi: 10.21037/tau.2020.01.11.

本文引用的文献

1
Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):252-9. doi: 10.1016/j.ijrobp.2015.01.007. Epub 2015 Mar 5.
2
Diagnosis, treatment and outcome of adrenocortical cancer.
Br J Surg. 2015 Mar;102(4):291-306. doi: 10.1002/bjs.9743.
3
Improving Outcomes in Adrenocortical Cancer: An Australian Perspective.
Ann Surg Oncol. 2015 Jul;22(7):2309-16. doi: 10.1245/s10434-014-4133-4. Epub 2014 Oct 16.
4
Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States.
Ann Surg Oncol. 2014 Oct;21(11):3509-14. doi: 10.1245/s10434-014-3931-z. Epub 2014 Jul 29.
5
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.
Eur J Endocrinol. 2013 Oct 23;169(6):891-899. doi: 10.1530/EJE-13-0519. Print 2013 Dec.
6
Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?
Surg Endosc. 2013 Nov;27(11):4026-32. doi: 10.1007/s00464-013-3034-0. Epub 2013 Jun 14.
7
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Eur J Endocrinol. 2013 Jul 29;169(3):263-70. doi: 10.1530/EJE-13-0242. Print 2013 Sep.
9
The role of surgery in the management of recurrent adrenocortical carcinoma.
J Clin Endocrinol Metab. 2013 Jan;98(1):181-91. doi: 10.1210/jc.2012-2559. Epub 2012 Nov 12.
10
Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma.
Ann Surg. 2012 Feb;255(2):363-9. doi: 10.1097/SLA.0b013e3182367ac3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验